Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP) announced the appointment of Dr. Freda Lewis-Hall, DFAPA, MFPM, to its board of directors, where she will also serve as chair of the company’s Scientific Advisory Committee, subject to approval by Cboe Canada. Dr. Lewis-Hall brings more than 40 years of experience across clinical care, research, academia and senior biopharmaceutical leadership, including more than a decade on Pfizer’s executive leadership team as executive vice president and chief medical officer, as well as leadership roles at Vertex Pharmaceuticals, Bristol Myers Squibb, Pharmacia Corporation and Eli Lilly and Company.
A Distinguished Fellow of the American Psychiatric Association and former advisor to the National Institute of Mental Health, Dr. Lewis-Hall will provide scientific, clinical and regulatory governance across Helus’ portfolio as the company advances its novel serotonergic agonist programs targeting serious mental health conditions. The appointment underscores Helus Pharma’s commitment to addressing the large unmet need for people who suffer from depression, anxiety, and other mental health conditions.
Helus Pharma, the commercial operating name of Cybin Inc., is a clinical stage pharmaceutical company focused on developing proprietary NSAs – novel serotonergic agonists: synthetic molecules designed to activate serotonin pathways that are believed to promote neuroplasticity. The company is currently developing HLP003, a proprietary NSA in Phase 3 clinical development for the adjunctive treatment of major depressive disorder that has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration, and HLP004, a proprietary NSA in Phase 2 for generalized anxiety disorder. Additionally, Helus Pharma has an extensive research portfolio of investigational NSAs.
The appointment of Dr. Lewis-Hall is expected to strengthen Helus Pharma’s scientific leadership as it progresses its pipeline. Her extensive experience in drug development and regulatory affairs will be invaluable as the company aims to improve the treatment landscape through the introduction of NSAs that aim to provide durable improvements in mental health. For more information about the appointment, visit the full press release here.
Helus Pharma operates in Canada, the United States, the United Kingdom and Ireland. For Company updates and to learn more about Helus Pharma, visit www.helus.com or follow the team on X, LinkedIn, YouTube and Instagram. Helus Pharma is a trademark of Cybin Corp.
